How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

XE

NASDAQ:XENE
Get a brief AI stock analysisSaves ~ 15 minutes of your time

XE

Xenon Pharmaceuticals IncNASDAQ XENE Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is XENE undervalued compared to its fair value?

The fair value of XENE stock is hidden USD. Relative to the market price of 43.78 USD Xenon Pharmaceuticals Inc is hidden.

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 203 full-time employees. The company went IPO on 2014-10-17. Th...[More about valuation]

Xenon Pharmaceuticals Fair Value

Available for registered user
UNLOCK
What is fair value?

Market cap:

3.304 $B

Price:

43.78 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.639

FINANCIALS

Xenon Pharmaceuticals financial for reporting period

Income Statement


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.054 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.045 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

Balance Sheet

0.96 B
0.93 B

Financial Position Analysis

Assets

0.96 B
Current Assets
0.64 B
Total non-current assets
0.32 B

Total current liabilities
0.027 B
Total non-current liabilities
0.0096 B

Cash Flow Statement

-0.036 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.035 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Xenon Pharmaceuticals fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Xenon Rating

Is XENE attractive for investment based on fundamental analysis?

XENE stock rating is hidden. Xenon Pharmaceuticals is a hidden by Eyestock methodology.

Get XENE Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

Debt / Equity ratio:

ROE:

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

XENE analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for XENE to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Xenon Pharmaceuticals Inc dividends

XENE dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About XENE stock

About the company Xenon Pharmaceuticals Inc

Market cap $B

3.304

Dividend yield

Shares outstanding

63.038 B

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 203 full-time employees. The company went IPO on 2014-10-17. The firm is focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The firm is focused on advancing its ion channel neurology pipeline. The firm's products within its novel proprietary pipeline include clinical-stage candidates XEN496 and XEN1101, which are focused on treating neurological disorders, with a particular focus on epilepsy. XEN1101 is a differentiated Kv7 potassium channel opener being developed for the treatment of epilepsy and major depressive disorder (MDD). The XEN496 is a Kv7 potassium channel opener, is a pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy, or KCNQ2-DEE. The firm has promising partnered products within its pipelines, such as NBI-921352 with Neurocrine Biosciences and PCRX301 with Pacira BioSciences.

XENE profile

  • Ticker

    XENE

  • Country

    Canada

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    17 October 2014

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    203

  • City

    Vancouver

  • Address

    3650 Gilmore Way

  • Cusip

    98420N105

Frequently Asked Questions

What sector does Xenon operate in?

Xenon operates in Healthсare sector

What is market cap of Xenon?

Market cap of Xenon is 3.304 USD as of 24 Jul 2024

What is market price of one XENE stock?

Market price of one XENE stock is 43.78 USD as of 24 Jul 2024

What is Xenon revenue?

According to the recent report Xenon revenue is —

What is Xenon net income?

According to the recent report Xenon net icnome is -44.743

What is Xenon net income growh rate?

Net income growth rate of Xenon is —